Gefitinib enhances sensitivity of endometrial cancer cells to progestin therapy via dual-specificity phosphatase 1

In this study, we investigated if Gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, augments endometrial cancer (EC) therapy with medroxyprogesterone acetate (MPA). Combined treatment with Gefitinib plus MPA decreased the proliferation and invasiveness of the Ishikawa and RL952 EC cel...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Yang, Yuan, Zhou, Jingyi, Li, Xiaoping, Zhao, Lijun, Cheng, Yuan, Lin, Yanying, Wang, Jiaqi, Wei, Lihui, Dong, Yafeng, Wang, Jianliu
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2017
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5777777/
https://ncbi.nlm.nih.gov/pubmed/29383165
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23264
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires